Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: BriaCell Therapeutics Corp.
Announced that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics Corp., a wholly-owned subsidiary of the Company pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCd) inhibitors for multiple indications including cancer, will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act (British Columbia). “As we focus our efforts on the upcoming pivotal study of our lead clinical candidate, Bria-IMT™, in advanced metastatic breast cancer, we believe that this strategy of spinning out certain pre-clinical immunotherapies in a separate entity of BriaPro Therapeutics Corp. will position them for success and will create our shareholders value over the long term,” stated Dr. William V. Williams, BriaCell’s President and CEO. “We continue with our mission to develop novel immunotherapies to fight cancer and improve patients’ lives whose medical needs are currently unmet.” BriaCell Therapeutics Corp. shares T.BCT are trading off 29 cents at $8.19.
